SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-151963
Filing Date
2024-05-31
Accepted
2024-05-31 17:24:29
Documents
13
Period of Report
2024-05-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d845254d8k.htm   iXBRL 8-K 23676
  Complete submission text file 0001193125-24-151963.txt   141950

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fate-20240530.xsd EX-101.SCH 2877
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20240530_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20240530_pre.xml EX-101.PRE 10830
17 EXTRACTED XBRL INSTANCE DOCUMENT d845254d8k_htm.xml XML 3541
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 241010852
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)